Mohammad Ismail, MD
Nephrology · Paramount, CANPI 1730105784
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,324 of the $5,509 with a category attached, or 60.3%. 15 manufacturers reported payments, led by Amgen at 45.0% of the total. Reporting peaked in 2020 at $2,271 and has fallen 88.2% since, to $267 in 2025.
Across 77 payments — averaging $71.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$664
- Bayer$407
- Otsuka America Pharmaceutical, Inc.$364
- Aurinia Pharma U.S., Inc.$345
- Sanofi-aventis U.S. LLC$296
- plus $953 from 9 others
Across 60 payments — averaging $10,599 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$585K
- Merck$41K
- GSK$7K
- AbbVie$2K
What the payments were for
- Speaking & faculty fees$2,16039%
- Food & beverage$3,32460%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 17 | $2,479 |
| AstraZeneca(2 entities) | 11 | $664 |
| Bayer | 12 | $407 |
| Otsuka America Pharmaceutical, Inc. | 8 | $364 |
| Aurinia Pharma U.S., Inc. | 6 | $345 |
| Sanofi-aventis U.S. LLC | 2 | $296 |
| Akebia Therapeutics Inc | 6 | $248 |
| Vifor Pharma, Inc. | 3 | $184 |
| Ardelyx, Inc. | 3 | $156 |
| GSK | 2 | $135 |
| Travere Therapeutics, Inc. | 1 | $95 |
| Fresenius USA Marketing, Inc. | 3 | $91 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $13 |
| OPKO Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,509 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 44 | $167,870 |
| FarxigaDapagliflozin Propanediol | 137 | $100,564 |
| Sevelamer Carbonate | 132 | $31,851 |
| TradjentaLinagliptin | 13 | $17,458 |
| TrulicityDulaglutide | 15 | $16,657 |
| DapagliflozinDapagliflozin Propanediol | 19 | $12,623 |
| LokelmaSodium Zirconium Cyclosilicate | 19 | $12,440 |
| JardianceEmpagliflozin | 12 | $10,172 |
| Cinacalcet Hcl | 26 | $8,469 |
| Clonidine | 23 | $5,280 |
| Midodrine Hcl | 38 | $3,413 |
| Nifedipine ErNifedipine | 75 | $2,219 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,159 |
| Calcium Acetate | 32 | $1,843 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $91 | $167,87044 claims |
| AstraZenecaFarxiga, Lokelma | $664 | $113,004156 claims |
| GSKArnuity Ellipta | $135 | $2,15911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,341 nephrology providers in California.
Other nephrology in Paramount
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.